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Objectives. Our purpose was to evaluate the relation between 
smoking and the outcomes of patients receiving thrombolysis for 
acute myocardial infarction. 
Background. A paradoxic beneficial effect has been observed in 
smokers with a myocardial infarction. We analyzed outcomes and 
baseline characteristics of11,975 nonsmokers, 11,117 ex-smokers 
and 17,507 current smokers in a multinational trial of thrombol- 
ysis for acute myocardial infarction. 
Methods. Patients were randomized to one of four thrombolytic 
protocols. An angiographic substudy in 2,431 patients evaluated 
reperfusion, reocclusion and ventricular function. Effects of smok- 
ing were evaluated by logistic regression analysis after adjustment 
for age and gender. A mortality model evaluated the simultaneous 
effect of baseline characteristics on the prognostic importance of 
smoking. These processes were performed with data from both the 
main trial and the angiographic substudy; then angiographic 
factors (coronary anatomy, patency and ejection fraction) were 
added to the model. 
Results. Smokers were significantly ounger by a mean of 11 
years) and had less comorbidity or severe coronary artery disease 
than nonsmokers. Nonsmokers had significantly higher hospital 
and 30-day mortality rates (9.9% and 10.3%, respectively) than 
smokers (3.7% vs. 4%, respectively, both p < 0.001) and more 
in-hospital complications. The unadjusted odds ratio for 30-day 
mortality in nonsmokers was 3.36 (95% confidence interval [CI] 
2.08 to 5.41), 1.21 (95% CI 0.71 to 2.08) after adjustment for age 
and gender and 1.08 (95% CI 0.59 to 1.96) after adjustment for all 
clinical baseline characteristics. 
Conclusions. Smokers receiving thrombolysis for acute myocar- 
dial infarction presented 11 years earlier than nonsmokers, which 
generally accounted for their better outcome. When other differ- 
ences in clinical and angiographic baseline factors and therapeu- 
tic responses were evaluated, no significant difference inmortality 
was seen between smokers and nonsmokers. 
(J Am Coil Cardiol 1995;26:1222-9) 
Despite many epidemiologic studies (1-4) showing that ciga- 
rette smoking is associated with higher rates of myocardial 
infarction and death from coronary artery disease, several 
large clinical trials have demonstrated that smokers who have 
an acute myocardial infarction have a better prognosis than 
nonsmokers (5-7). It has been proposed (7) that this paradox 
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occurs because smokers who present with myocardial infarc- 
tion differ as to extent of coronary vessel disease and have 
lesions that are more thrombogenic than atherogenic. Although 
the population of patients with myocardial infarction treated 
with thrombolytic therapy is relatively low risk, it provides an 
ideal cohort o study the epidemiology of risk factors. 
The first Global Utilization of Streptokinase and Tissue- 
Plasminogen Activator for Occluded Coronary Arteries 
(GUSTO-I) trial (8), with its angiographic substudy (9), pro- 
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vided an opportunity to explore this paradox by correlating 
clinical outcomes with baseline clinical characteristics and the 
extent and nature of coronary artery disease in a large number 
of smoking and nonsmoking patients with acute myocardial 
infarction. We report he results of an analysis of the effects of 
smoking in the GUSTO-I population. 
Methods  
Patient population. Thrombolytic therapy. Overall, 41,021 
patients with acute evolving myocardial infarction were ran- 
domized to receive one of four intravenous thrombolytic 
strategies according to the GUSTO-I protocol: 1) 1.5 million U 
of streptokinase over 60 min with subcutaneous heparin 
(12,500 IU) twice daily beginning 4 h after initiation of 
thrombolytic therapy; 2) 1.5 million U of streptokinase over 
60 min with an intravenous heparin bolus of 5,000 U, then 
1,000 U/h, adjusted to maintain an activated partial thrombo- 
plastin time of 60 to 85 s; 3) accelerated recombinant tissue- 
type plasminogen activator (rt-PA) (15-mg bolus), then 
0.75 mg/kg body weight over 30 min (not to exceed 50 mg), 
then 0.5 mg/kg (up to 35 mg) over the next 60 min with the 
same intravenous heparin regimen; or 4) the combination of 
intravenous rt-PA (1.0 mg/kg over 60 rain, not to exceed 90 mg, 
with 10% given as a bolus) and streptokinase (1.0 million U 
over 60 min) given simultaneously, followed by the same 
intravenous heparin regimen. The study design, inclusion and 
exclusion criteria, trial medications and guidelines for patient 
management have been described in detail elsewhere (8). 
Smoking status (current smoker, nonsmoker, ex-smoker) 
was obtained from the patient or a representative at the time 
of randomization, as was the average number of cigarettes 
smoked each day. Information on the duration of nonsmoking 
(for ex-smokers) was not available for analysis. Smoking status 
was not assessed uring hospitalization or after discharge. 
The clinical outcomes analyzed were hospital and 30-day 
mortality, in-hospital reinfarction, cardiogenic shock, conges- 
tive heart failure, major arrhythmias, troke, hemorrhage, and 
worst Killip class during the hospital stay. The baseline char- 
acteristics analyzed were age (->70 and 60 to 69 vs. <60 years), 
gender, weight, infarction site, diabetes mellitus, previous 
infarction, antecedent angina, hypertension, smoking status, 
family history of cardiovascular disease, hypercholesterolemia, 
Killip class at entry (>I vs. I) and time from onset of symptoms 
to treatment initiation (>3 vs. -<3 h). 
Angiographie studies. In the angiographic substudy (9), 
2,431 GUSTO-I patients were also randomly assigned to 
undergo cardiac atheterization atone of four times after the 
initiation of thrombolytic therapy: 90 rain, 180 min, 24 h or 5 to 
7 days. Patients who had a 90-rain study also had a 5- to 7-day 
follow-up angiogram. The principal end points for the angio- 
graphic substudy were infarct-related artery patency, reocclu- 
sion and left ventricular function. The angiographic study 
protocol and methods of analysis have been described in detail 
elsewhere (9). The films were analyzed in blinded manner with 
regard to treatment assignment or clinical data. Both coronary. 
and ventriculographic analyses were performed using repro- 
ducible, quantitative t chniques. 
Statistical methods. Baseline characteristics and clinical 
outcomes were tested by means of a chi-square test for trend 
for discrete variables and by analysis of variance for continuous 
variables. Angiographic characteristics (anatomy, extent of 
disease and left ventricular dysfunction) were compared for 
nonsmokers versus current smokers and for nonsmokers versus 
current and ex-smokers combined. This was done under the 
prospective assumption that the ex-smokers would have risk 
factors and outcomes of intermediate severity compared with 
nonsmokers and current smokers but that would be closer to 
those of the current smokers. Nominal p values are reported 
for each comparison, although caution must be exercised in the 
interpretation of these values. This study represents an ancil- 
lary analysis of a large data base with multiple purposes; 
accordingly, the statistical comparisons reported herein repre- 
sent a fraction of the total comparisons performed on the data 
base. The issue of multiplicity must be considered because 
some of these comparisons would be expected to be nominally 
"statistically significant" by chance. In addition, given the large 
sample size of this study, a "significant" comparison must be 
scrutinized for clinical relevance because small, clinically un- 
important differences can have small p values. 
To maximize the explanatory function of the statistical 
models to predict outcomes and to avoid repeating modeling 
processes already completed on the GUSTO-I data base, we 
proceeded by means of a prespecified modeling strategy. 
1. The entire GUSTO-I clinical data base was used to 
examine the relation between smoking and mortality after 
adjusting for other features of the patients. Initially, the effects 
of smoking were evaluated using logistic regression analysis 
after adjusting for only age and gender. A previously devel- 
oped (10) detailed mortality model was then used to evaluate 
the simultaneous impact of multiple baseline characteristics on
the prognostic mportance of smoking. This model includes the 
following additional prognostic variables: systolic blood pres- 
sure; Killip class; heart rate; location of infarction; previous 
myocardial infarction; previous bypass urgery; height; time to 
thrombolytic therapy; type of thrombolytic therapy; weight; 
and previous diabetes, hypertension or cerebrovascular dis- 
ease. 
2. The smaller (2,431 patients) angiographic substudy (9) 
data base was then interrogated, first adjusting for only age and 
gender, then adjusting again for the entire clinical model. 
Because the power to detect significant differences was mark- 
edly lower in the angiographic substudy data base, we were 
most interested in the magnitude of the estimated effect rather 
than its statistical significance. 
3. The angiographic factors of left ventricular ejection 
fraction, Thrombolysis n Myocardial Infarction (TIMI) grade 
3 flow, and the number and extent of lesions were included in 
the model. In each case, the effect of smoking was character- 
ized after adjusting for all prognostic factors thought o be 
important. 
Odds ratios and 95% confidence intervals for 30-day mor- 
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Table 1. Baseline Characteristics 
Nonsmokers Ex-Smokers Current Smokers p 
(n - 11,975) (n - 11,117) (n = 17,507) Value* 
Male gender 7,315 (61) 9,438 (85) 13,629 (78) < 0.00l 
Age (yr) 65.9 +_ 11.5 64.1 _+ 10.3 55.4 ± 10.9 < 0.001 
Weight (kg) 77.1 _+ 15.6 81.8 ± 15.1 79.6 + 15.8 < 0.001 
Family H× CVD 4,323 (38) 4584 (43) 7,598 (45) < 0.001 
Hypertension 5,329 (45) 4,753 (43) 5,304 (30) < 0.00l 
Diabetes 2,273 (19) 1,852 (17) 1,792 (10) < 0.00l 
Hypercholesterolcmia 3,861 (33) 3,975 (37) 5,668 (33) < 0.00l 
Previous infarction 1,821 (15) 2,516 (23) 2,267 (13) < 0.00l 
Antecedent angina 4,355 (37) 4,673 (42) 5,869 (34) < 0.00l 
Infarction location 
Anterior 5,400 (45) 4,112 [37) 6,265 (36) 
Inferior 6.071 (51) 6,566 (59) 10,664 (61) < 0.00l 
Other 466 (4) 399 (4) 531 (3) 
Systolic BP (ram Hgi 140.5 ~ 3(I.1 140.4 + 30.2 136.1 ± 29.6 < 0.001 
Diastolic BP (ram Hg) 84.5 - 17.9 85.1 + 17.9 84.4 ± 18.2 0.143 
Heart rate (beats/rain) 75.3 = 17.9 74.8 ± 17.5 75.7 ± 17.2 < 0.001 
Initial Killip class 
[ 10.093 (85) 9,420 (85) 15,026 (86) 
II 1,512 (13) 1,447 (13) 2,1 lO (12) 
Ill 202 (1.7) 147 (1.3) 178 (1.0) < 0.00l 
IV 118 (1.0) 60 (0.5) 110 (0.6) 
Time to treatment (h) 3.2 -- 1.65 3.09 - 1.64 3.03 +- 1.59 < 0.001 
*Chi-squarc test for trend, comparing current smokers, ex-smokers and non-smokers as three groups. Data presented 
arc number (~) of patients or mean value + SD. BP - blood pressure; CVD = cardiovascular disease; Fix = history. 
tality were calculated using standard methods. Odds ratios 
computed from the logistic oefficients are presented, followed 
by 95% confidence limits computed on the basis of the 
standard error of the coefficients. Categoric variables are 
presented as number and percent of patients with the charac- 
teristic; continuous variables are given as mean value _+ SD. 
Results 
Study population. Of the 41,021 patients randomized, 
smoking status was not defined in 380 patients (0.9%) and 
baseline data on an additional 42 patients (0.1%) were missing. 
Thus, 40,599 patients were included in the present analysis 
(11,975 nonsmokers, 11,117 ex-smokers and 17,507 current 
smokers). The baseline characteristics of the three groups 
differed significantly (Table 1). Nonsmokers had consistently 
worse baseline characteristics than current smokers: they were 
older and had a higher ate of hypertension, diabetes mellitus, 
anterior wall infarction and Killip class >I at admission. With 
the exceptions of angina and previous myocardial infarction, 
the rates in ex-smokers were intermediate between current 
smokers and nonsmokers. Smokers were treated an average of 
10 min earlier than nonsmokers. All of these differences were 
highly significant. 
Angiographic findings: evidence of different pathogenesis. 
A total of 2,431 patients were enrolled in the angiographic 
substudy and underwent coronary angiography during the 
index hospital stay. Current smokers had a significantly higher 
rate of single-vessel coronary artery disease (Table 2). Current 
smokers had more right coronary artery occlusion (49%) than 
ex-smokers (47%) or nonsmokers (38%, p < 0.0001). There 
was a significant difference in 90-rain perfusion; 41% of current 
and ex-smokers had TIMI grade 3 flow in the infarct-related 
artery compared with only 33% of nonsmokers (p = 0.02). At 
90-min coronary angiography, intracoronary thrombus was 
documented in a similar percent of each patient group. 
There was no difference among the three groups in minimal 
lumen diameter or percent stenosis nor in the amount of 
change for these variables from initial to follow-up angiogra- 
phy (Table 3). A significantly ower rate of in-hospital reocclu- 
sion was observed in smokers than in nonsmokers and ex- 
smokers (2.7% vs. 7.7% and 9.8%, respectively, p < 0.01). 
12ft ventricular function. Table 4 summarizes the analysis 
of left ventricular function relative to smoking status. Current 
smokers had the highest left ventricular ejection fraction, with 
the ex-smokers as an intermediate group. Compared with 
nonsmokers, current and ex-smokers had significantly less 
depression of regional wall motion in the ischemic zone, as 
expressed by the smaller number of abnormal chords. 
In.hospital clinical outcomes. Table 5 presents in-hospital 
clinical outcomes. Nonsmoking patients had the worst in- 
hospital outcomes, mokers the best, with ex-smokers consti- 
tuting an intermediate group. Specifically, the nonsmoking 
patients had higher rates of reinfarction; congestive heart 
failure; or pulmonary edema, shock, strokes (including primary 
hemorrhagic and nonhemorrhagic strokes), moderate-to- 
severe bleeding and more severe Killip class. These differences 
were all statistically significant. 
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Table 2. Coronary. Anatomy 
Current Smokers p Values 
Nonsmokers Ex-Smokers < 20 Cig/Day >20 Cig/Day Total Current/Ex-Smokers vs. Current vs. 
(n - 644) (n = 599) (n = 716) (n 328) (n = 1,044) Nonsmokers Nonsmokers 
Vessels diseased (no.) 
1 356 (55.3) 317 (52.9) 437 (61.11) 221 (67.4) 658 (63.0) 0.076 0.002 
2 154 (23.9) 160 (26.7} 167 (23.3) 61 (18.6) 228 (21.8) 0.88 0.323 
3 117(18.2) 1116(17.7) 87 (12.2) 38(11.6) 125 (12.0) 0.014 0.001 
0 17 (2.6) 16 (2.7) 25 (3.5) 8 (2.4) 33 (3.2) {).66 0.54 
Infarct-related artery n -: 629 n = 591 n - 662 n - 327 n = 989 
LAD 302 (47.1) 2(10 (33.6) 228 (34.4) 113 (34.5) 341 (34.4) < 0.0001 < 0.0001 
LCx 71 (11.1) 85 (14.3) 83 (12.5) 38 {11.6) 121 (12.2) 0.3 0.36 
RCA 243 (37.9) 277 (46.5) 320 (48.3) 163 (50.6) 483 (48.8) < 0.0001 < 0.0001 
LMCA 0 3 (0.5) 3 (0.4) 3 (0.9) 6 (0.6) 0.05 0.04 
SVG 13 (2.0) 26 (4.4) 16 (2.4) 6 (1.8) 22 (2.2) I).19 0.79 
TIMI flow grade (90min) n 297 n 272 n 361 n 162 n =523 
0 74 (24.9) 63 (23.1} 86 (23.8l 42 (25.9) 128 (24.5) 0.76 0.89 
1 27 (9.1) 20 (7.4) 25 (6.9) 16 (9.8) 41 (7.8) 0.44 0.53 
2 98 (33.1!} 76 (27.9) 98 (27.2} 42 (25.9) 140 (26.8) 0.06 0.05 
3 98 (33.1)} 113 (41.5) 151 (41.9} 62 138.2) 213 (40.8) 0.01 0.02 
Visible thrombus (90 rain) 2/)0 (62.7} 176 (64.7) 223 (62.1) 104 (64.1) 327 (62.7) 0.79 1.00 
Data presented are number (%) of patients. Cig = cigarettes; LAD = left anterior descending coronary artery; LCx - left circumflex coronary artery; LMCA = 
left main coronary artery; RCA right coronary artery; SVG - saphenous vein bypass graft: TIMI - Thrombolysis in Myocardial Infarction. 
Table 3, Corona~ Arte U Lesion and Vascular Characteristics 
p Value 
Current/Ex- vs. Current vs, 
Nonsmokers Ex-Smokers Current Smokers Nonsmokers Nonsmokers 
90-min angiogram 
MLD (ram) 0.78 -~ 0.41 0.83 _+ 0.49 0.81 ± 0.42 (I.354 (I.428 
% diameter stenosis 69.3 _+ 15.9 71.7 ± 14.1 70.6 ± 14.2 0.201 0.347 
5-7 day angiogram 
MLD (ram) 0.89 + 0.44 0,92 ± 0.52 0.92 ± 0.45 0.475 0.468 
% diameter stenosis 67.1 + 14.6 68.9 _+ 13.7 66.9 ± 14.5 0.708 0.913 
Change in 
Lesion diameter (ram) 0.13 -+ 0.39 0.09 ± 0.44 0,13 ± 0.41 0,637 0.841 
% diameter stenosis -3.8 ± 13.7 -3.4 _~ 14.1 4.2 ± 14.6 0,949 (}.807 
Reocclusion (%) 7.7 9.8 2,7 0.305 0.021 
Data presented arc mean value _+ SD or percent of patients. MLD = minimal umen diameter. 
Table 4, Left Ventricular Function 
p Value 
Nonsmokers Ex-Smokcrs Current Smokers Current/Ex- vs. Current vs. 
(mean ± SD) (mean ± SD) (mean ± SD) Nonsmokers Nonsmokers 
Ejection fraction at 90 min (%) 
Change in ejection fraction at 7 days (~) 
End-systolic volume index (ml/m 2) 
Wall motion (SD/cbord)* 
No. of abnormal chordsf 
56.6 z 15.7 58.1 z 14.8 59.1 -+ 14.5 0.04 0.03 
-I).6 -+ 11.8 -0.8 ~ 12.3 -0.2 + 11.6 0.78 0.70 
29.8 + 17.5 27.4 ~ 15.11 28.5 -_ 16.2 0.19 0.35 
2.6 ± 1.4 2.4 +_ 1.6 -2.4 + 1.5 0.11 0.16 
26.2 _+ 18.5 21.9 + 17.6 22.1 ± 17.9 0.001 0.004 
*Mean magnitude of depressed infarct zone chords: wall motion was considered preserved if all infarct-zone chords were normal. +Chords in the infarct zone were 
considered abnormal if they were >2 SD below the norm. 
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Table 5. In-Hospital Clinical Outcomes 
Nonsmokers Ex-Smokers Current Smokers p 
(n = 11,975) (n = 11,117) (n = 17,507) Value* 
Mortality 
In-hospital 1,179 (9.9) 703 (6.3) 652 (3.7) < 0.001 
30-Day 1,225 (10.3) 747 (6.7) 697 (4) < 0.001 
Death or stroke 1,342 (11.2) 865 (7.8) 805 (4.6) < 0.001 
Death/disabling stroke 1,296 (10.8) 816 (7.3) 761 (4.4) < 0.001 
Stroke 217 (1.8) 191 (1.7) 172 (1.0) < 0201 
Hemorrhagic 99 (0.8) 79 (0.7) 83 (0.5) < 0.001 
Nonhemorrhagic 79 (0.7) 88 (0.8) 76 (0.4) 0.006 
Hemorrhagic conversion 17 (0.1) 9 (0.1) 8 (0.1) 0.006 
Nonhemorrhagic 79 (0.7) 88 (0.8) 76 (0.4) 0.006 
Unknown 22 (0.18) 15 (0.14) 5 (0.03) < 0.001 
Reinfarction 570 (4.8) 528 (4.8) 508 (2.9) < 0.001t 
Recurrent ischemia 2,512 (21) 2,533 (23) 3,023 (17) < 0.001¢ 
AV block 983 (8.2) 876 (7.9) 1,45l (8.3) 0.456 
Ventricular fibrillation 750 (6.3) 741 (6.7) 1,169 (6.7) 0.313 
Ventricular tacbycardia 693 (5.8) 688 (6.2) 1,095 (6.3) 0.233 
Pacemaker insertion 856 (7.2) 841 (7.6) 1,103 (6.3) < 0.001t 
CHF or pulmona~ edema 2,242 (18.8) 1,923 (17.3) 2,362 (13.5) < 0.001 
Shock 878 (7.4) 643 (5.8) 814 (4.7) < 0.001 
Moderate to severe bleeding 1,892 (16) 1,466 (13) 1,754 (10) < 0.001 
Worst Killip class 
I 7.499 {63) 7,052 (64) 11,984 (69) 
11 3,029 (25) 2,974 (27) 4,207 (24) 
11I 644 (5) 523 (5) 612 (4) < 0.001 
IV 726 (6) 493 (4) 579 (3) 
*Chi-square test for trend, unless otherwise indicated, comparing current smokers, ex-smokers and nonsmokers as 
three groups, tChi-square test. Data presented are number (%) of patients. AV = atrioventricular; CHF = congestive 
heart failure. 
Mortality. In-hospital and 30-day mortality rates were 
higher for nonsmokers than for ex- or current smokers (p < 
0.001) (Fig. 1, Table 5). Discharge to 30-day mortality was also 
higher in nonsmokers and ex-smokers than in smokers (0.4% 
for nonsmokers and ex-smokers vs. 0.3% for smokers, p < 
0.001). Both in-hospital and 30-day mortality significantly 
decreased in smokers as the number of cigarettes smoked each 
day increased (p < 0.001) (Fig. 2, top). This pattern was 
Figure 1. In-hospital (open bars) and 30-day mortality (solid bars) 
according to smoking status, p < 0.001 for both hospital and 30-day 
mortality by chi-square test for trend, comparing nonsmokers, ex- 
smokers and active smokers as three groups. 
121 10.3 ( 
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Figure 2. In-hospital (open bars) and 30-day mortality (solid bars) in 
current smokers by number of cigarettes smoked per day, unadjusted 
(top) and after adjustment for age and gender (bottom). Independent 
association between mortality and number of cigarettes moked was 
confirmed in a multivariable analysis accounting for all baseline 
variables. 
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maintained after adjustment for age and gender, although 
mortality did increase somewhat in the heaviest smokers (Fig. 
2, bottom). The effect of smoking status was similar for all four 
GUSTO-I treatment s rategies. 
Muhivariable analysis. The results of the multivariate anal- 
ysis are shown in Figure 3. When considered without regard to 
other covariates, nonsmoking status was associated with sub- 
stantially higher 30-day mortality. A portion of this smoking 
effect was explained by the fact that the nonsmokers were older 
and tended to be women. When the entire mortality model was 
used, current smoking status remained independently associ- 
ated with lower mortality (odds ratio [OR] 1.25 for nonsmok- 
ers vs. current smokers, 95% confidence interval [CI] 1.11 to 
1.39). When the angiographic substudy population was exam- 
ined separately, the odds ratios were quite similar to those for 
the entire population, although the tests were less significant 
(unadjusted OR 3.36 for 30-day mortality in nonsmokers in the 
substudy, 95% CI 2.08 to 5.41). When age and gender were 
accounted for, the odds ratios continued to favor smokers, 
although the comparison was no longer significant (OR 1.21, 
95% CI 0.71 to 2.08). The odds ratio decreased further after 
adjustment for all baseline clinical variables (OR 1.08, 95% CI 
0.59 to 1.96) and after adjustment for differences in clinical 
characteristics, oronary anatomy and left ventricular dysfunc- 
tion (OR 0.93, 95% CI 0.46 to 1.88). 
Discuss ion  
An increased mortality risk from coronary artery disease 
has long been associated with smoking (1-4). However, there 
is evidence (5-7,11-21) that smokers who are admitted to the 
hospital for acute myocardial infarction have a significantly 
better outcome than nonsmokers and, in most aspects, than 
patients who stopped smoking before their myocardial infarc- 
tion (7). These apparently contradictory results have been 
explained in some studies by the poorer baseline risk profile of 
Figure 3. Odds ratios (squares) and 95% confidence intervals (hori- 
zontal ines) for mortality in current smokers versus nonsmokers 
before and after adjustment for various confounding factors (see 
Methods for clinical variables). Angiographic factors include 90-min 
Thrombolysis in Myocardial Infarction flow grade, ejection fraction 
and extent and location of lesions. Values >1 indicate an increased 
mortality risk with nonsmoking status; values <1 denote an increased 
mortality risk with current smoking status. 
the nonsmoking patients (13-16). Smokers have been found to 
be significantly ounger and to have a more favorable risk 
profile at admission (7,14-21). The increased in-hospital mor- 
tality found in nonsmokers in the present study was further 
corroborated by the significantly higher mortality seen in 
current smokers as the numbers of cigarettes smoked each day 
decreased (p < 0.001) (Fig. 2). 
Several potential explanations have been offered for this 
"smoker's paradox," including the theory that a large propor- 
tion of current smokers suffer prehospital sudden deaths 
(22-24). Others (25) have postulated some favorable effect 
that the sudden withdrawal of cigarettes may have on vascular 
and hematologic variables. 
Different pathogenesis.  Our results, obtained from analy- 
ses of >40,000 patients with acute myocardial infarction and 
corroborated by results of a 2,400-patient angiographic sub- 
study, provide a partial mechanistic explanation for the "smok- 
er's paradox." These data support he hypothesis (7) that the 
type of lesion that precipitates myocardial infarction in smok- 
ers is less severe and may be generated by a different mecha- 
nism. 
1. Our results confirm earlier observations (16,21,26) that 
angiographically recorded coronary lesions may be less exten- 
sive in smokers. In the Coronary Artery Surgery Study (CASS) 
registry (26), the extent of coronary disease (total number of 
segments with ->50% stenosis) was significantly less in male 
smokers >45 years old than in nonsmokers. In the TIMI II 
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study, current smokers had significantly ess multivessel disease 
than ex-smokers and nonsmokers and fewer infarctions of the 
left anterior descending artery. (16). In the GUSTO-I angio- 
graphic substudy, current smokers had a significantly higher 
rate of single-vessel disease. 
2. As in earlier eports (16,27), smokers in GUSTO-I had 
more right coronary artery infarctions (49% vs. 38%, p < 
0.0001) than nonsmokers. Inview of the conflicting data on the 
influence of infarct location on arterial patency after throm- 
bolytic therapy (27), it is not clear whether this lesion distri- 
bution is related to the higher patency rates observed in 
smokers in the present study. It may suggest that lesions in the 
right coronary artery are more thrombogenic, perhaps related 
to the phasic flow in the right coronary artery, differing from 
that in the left anterior descending coronary artery because of 
the lower systolic ompressive forces in the right ventricle (28). 
3. TIMI grade 3 flow in the infarct-related artery was found 
at the 90-rain coronary angiography in a larger proportion of 
current and ex-smokers than nonsmokers (p = 0.02). In an 
analysis from the second Thrombolytic Trial of Eminase in 
Acute Myocardial Infarction (TEAM-2) (20), significantly 
more smokers than nonsmokers achieved complete patency 
(TIMI grade 3 flow). Similar to our observation, the increase in 
TIMI grade 3 flow in smokers was at the expense of grade 2 
flow, which was relatively overrepresented in nonsmokers (20). 
Current smokers also had significantly fewer angiographic 
reocclusions and clinical reinfarctions than nonsmokers and 
ex-smokers. 
Recently, thrombus volume has been found to be increased 
twofold in blood from cigarette smokers (exposed to high shear 
conditions typical of moderately stenosed arteries) (29). The 
similar incidence of visible thrombi in each group in our study 
and the lack of greater resolution at follow-up angiography in
smokers do not seem to support he hypothesis that smokers 
have more or larger thrombi initially than patients who have 
never smoked. However, the significantly lower extent of 
atherosclerotic coronary disease, higher incidence of nonan- 
terior wall infarctions, greater incidence of TIMI grade 3 flow 
at 90 min and significantly ower rate of reocclusion i  smokers 
do lend support o a more thrombogenic etiology of myocar- 
dial infarction in these patients (7). Thus, smoking patients 
with a myocardial infarction may respond better to either 
spontaneous or therapeutic thrombolysis. 
Study limitations. Although the present clinical trial pro- 
vides detailed ata about a well characterized population, only 
a minority of patients with acute myocardial infarction are 
candidates for thrombolytic therapy. Patients who are not 
candidates are older, more often female and have a higher 
mortality rate. Also, we could not provide potentially valuable 
information for ex-smokers about the duration of time since 
they had stopped smoking. 
Conclusions. Smokers in GUSTO-I presented an average 
of 11 years earlier than nonsmokers, which accounted for most 
of their survival advantage. They also constituted a large 
proportion of our patients (44%). Because smokers are more 
than twice as likely to have a myocardial infarction as non- 
smokers (30), the resulting mortality from myocardial infarc- 
tion in the general population isabout wice as high in smokers 
as in those who have never smoked (1,4). However, in one 
study (4) former smokers had a cardiovascular mortality rate 
approaching that of those who had never smoked, independent 
of the age at which smoking stopped. These findings argue for 
continuing vigorous efforts to prevent people from taking up 
smoking and encouraging smokers to quit. 
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